Target General Information
Target ID T88023 Target Info
Target Name Lymphocyte activation antigen CD30 (TNFRSF8)
Synonyms Tumor necrosis factor receptor superfamily member 8; KI-1 antigen; D1S166E; CD30L receptor; CD30
Target Type Successful Target
Gene Name TNFRSF8
UniProt ID
Targeted Antigens of CAR-T Cell Therapy
CAR T-Cell Therapy Drug(s) CAR-T cells targeting CD30 Drug Info Phase 2 Non-hodgkin lymphoma [1]
4SCAR19 and 4SCAR30 Drug Info Phase 1/2 B-cell lymphoma [2]
Anti-CD30 CAR T cells Drug Info Phase 1/2 Lymphoma [3]
Anti-CD30-CAR-transduced T cells Drug Info Phase 1/2 Lymphoma [4]
CAR-T cells targeting CD30 Drug Info Phase 1/2 Multiple myeloma [5]
CAR.CD30 cells Drug Info Phase 1/2 Neoplasm [6], [7]
CART30 Drug Info Phase 1/2 Non-hodgkin lymphoma [8]
Anti-CD30 CAR-T cells Drug Info Phase 1 Lymphoma [9]
Anti-CD30-CAR T cells Drug Info Phase 1 Lymphoma [10]
ATLCAR.CD30 cells Drug Info Phase 1 Neoplasm [11]
ATLCAR.CD30.CCR4 cells Drug Info Phase 1 Neoplasm [11]
CAR CD30 T cells Drug Info Phase 1 Non-hodgkin lymphoma [12]
CD30 CAR T Cells Drug Info Phase 1 Non-hodgkin lymphoma [13]
ICAR30 T cells Drug Info Phase 1 Hodgkin lymphoma [14]
References
REF 1 ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
REF 2 ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
REF 3 ClinicalTrials.gov (NCT02274584) CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
REF 4 ClinicalTrials.gov (NCT02958410) A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies
REF 5 ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
REF 6 ClinicalTrials.gov (NCT02663297) Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
REF 7 ClinicalTrials.gov (NCT02690545) Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
REF 8 ClinicalTrials.gov (NCT02259556) CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
REF 9 ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
REF 10 ClinicalTrials.gov (NCT03049449) T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
REF 11 ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL
REF 12 ClinicalTrials.gov (NCT01316146) Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)
REF 13 ClinicalTrials.gov (NCT02917083) CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
REF 14 ClinicalTrials.gov (NCT03383965) CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.